- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07946536
A Clinical Trial to Evaluate the Effects of Glow Shakes Premium Collagen Meal Replacement on Nutritional Adequacy, Body Composition, Skin Health, Satiety, and Overall Wellness in Adults Using GLP-1 or Dual-Incretin Medications for Weight Management
This is a single-group, open-label, decentralized clinical trial evaluating the effects of 12 weeks of once-daily consumption of Glow Shakes Premium Collagen Meal Replacement on nutritional adequacy, body composition, skin health, satiety, and overall wellness in 40 adults aged 18-55 years who are currently using a GLP-1 receptor agonist or dual-incretin medication for weight management. All study activities are conducted remotely; participants complete questionnaire assessments and smart scale body composition measurements at home at Baseline, Week 4, Week 8, and Week 12.
Participants replace a typical meal once daily with the study product for 12 consecutive weeks while continuing their existing GLP-1 or dual-incretin medication. The primary objective is to evaluate within-participant change in perceived nutritional adequacy from Baseline to Week 12. Secondary objectives include changes in body fat percentage, muscle mass, perceived skin health, hunger and satiety, hair health, energy and cognitive focus, nail health, gut comfort, metabolism support, physical strength, and product tolerability and satisfaction.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Izaak Woodley
- E-mail: izaakwoodley@thecollagen.co
Lieux d'étude
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89101
- Citruslabs
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adults aged 18-55 years at the time of enrollment.
- Currently using a GLP-1 receptor agonist or dual-incretin medication for weight management (e.g., semaglutide, tirzepatide, liraglutide) for a minimum of 4 weeks at the time of enrollment, with a stable or documented dose (no dose change within the 4 weeks prior to enrollment).
- Self-reported interest in supporting weight management, lean muscle maintenance, nutritional adequacy, or beauty-related benefits (e.g., skin, hair, nails) during GLP-1 therapy.
- Willing and able to use Glow Shakes Premium Collagen Meal Replacement as a once-daily meal replacement (replacing a typical meal) for 12 consecutive weeks and to complete all questionnaire assessments and Withings smart scale body composition measurements at Baseline, Week 4, Week 8, and Week 12.
- Willing and able to maintain current GLP-1 or dual-incretin medication dose throughout the study duration without planned dose adjustments (except in the event of a medically indicated change).
- Willing to maintain current diet (except for the study product), exercise routine, and lifestyle habits for the duration of the 12-week study, without introducing any new supplements or products specifically targeting weight loss, appetite, or body composition.
- In good general health.
- Resides in the United States.
Exclusion Criteria:
- Pregnant or breastfeeding at the time of enrollment, or planning to become pregnant during the 12-week study period.
- Known allergy or intolerance to any ingredient in the Glow Shakes formulation, including milk, whey, or collagen-derived ingredients.
- Diagnosed with a serious medical condition requiring medical nutritional management, including but not limited to Type 1 diabetes, active cancer, or severe renal or hepatic disease.
- Currently testing, or plan to in the next 12 weeks, a product for another research study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Glow Shakes Premium Collagen Meal Replacement Arm
|
Participants will consume one serving once daily - replacing a typical meal such as breakfast or lunch - for 12 consecutive weeks. One serving is prepared by adding the powder to 11.8 fl oz (approximately 350 mL) of water: add water first, then two scoops of powder, and shake for fewer than 10 seconds. Drink immediately after preparation. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Perceived Nutritional Adequacy
Délai: Baseline to Week 12
|
Within-participant change in perceived nutritional adequacy assessed via self-report questionnaire |
Baseline to Week 12
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Body Fat Percentage
Délai: Baseline to Week 12
|
Within-participant change in body fat percentage (%) measured by participant self-administered Withings smart scale |
Baseline to Week 12
|
|
Change in Muscle Mass
Délai: Baseline to Week 12
|
Within-participant change in muscle mass (kg) measured by participant self-administered Withings smart scale |
Baseline to Week 12
|
|
Change in Self-Reported Weight Management and Food Cravings
Délai: Baseline to Week 12
|
Within-participant change assessed via the validated Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced) |
Baseline to Week 12
|
|
Change in Self-Reported Perceived Skin Smoothness
Délai: Baseline to Week 12
|
Within-participant change in perceived skin smoothness score assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Perceived Skin Elasticity
Délai: Baseline to Week 12
|
Within-participant change in perceived skin elasticity score assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Hunger Intensity
Délai: Baseline to Week 12
|
Within-participant change in perceived hunger intensity assessed via visual analogue scale or equivalent validated hunger/satiety instrument |
Baseline to Week 12
|
|
Change in Self-Reported Satiety Duration
Délai: Baseline to Week 12
|
Within-participant change in perceived satiety duration assessed via visual analogue scale or equivalent validated hunger/satiety instrument |
Baseline to Week 12
|
|
Change in Self-Reported Food Craving Scores
Délai: Baseline to Week 12
|
Within-participant change in food craving scores assessed via the Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced) |
Baseline to Week 12
|
|
Change in Self-Reported Hair Thickness
Délai: Baseline to Week 12
|
Within-participant change in perceived hair thickness assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Hair Health
Délai: Baseline to Week 12
|
Within-participant change in perceived hair health assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Energy Levels
Délai: Baseline to Week 12
|
Within-participant change in perceived energy levels assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Cognitive Focus
Délai: Baseline to Week 12
|
Within-participant change in perceived cognitive focus assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Nail Thickness
Délai: Baseline to Week 12
|
Within-participant change in perceived nail thickness assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Nail Health
Délai: Baseline to Week 12
|
Within-participant change in perceived nail health assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Gut Comfort and Digestive Health
Délai: Baseline to Week 12
|
Within-participant change in gut comfort and digestive symptom scores assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Metabolism Support
Délai: Baseline to Week 12
|
Within-participant change in perceived metabolism support assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Physical Strength
Délai: Baseline to Week 12
|
Within-participant change in perceived physical strength assessed via self-report questionnaire |
Baseline to Week 12
|
|
Product Tolerability and Participant Satisfaction
Délai: Week 12
|
Participant-reported product satisfaction, acceptability, and tolerability assessed via product satisfaction questionnaire |
Week 12
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- THECO-73657
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .